Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
暂无分享,去创建一个
C. Tournigand | M. Buyse | C. Bokemeyer | E. Saad | C. Fuchs | E. Van Cutsem | C. Punt | R. Goldberg | F. Kabbinavar | H. Hurwitz | L. Saltz | J. Hecht | J. Zalcberg | J. Douillard | D. Sommeijer | M. Koopman | P. Hoff | N. Tebbutt | T. Burzykowski | A. Falcone | A. de Gramont | T. Maughan | Q. Shi | A. Gramont | H. Schmoll | E. Díaz-Rubio | E. Cutsem | E. Coart | M. Seymour | Tomasz Burzykowski | Tim Maughan
[1] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Collette,et al. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses , 2019, JNCI cancer spectrum.
[4] U. Mansmann,et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). , 2015, European journal of cancer.
[5] S. Barni,et al. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. , 2015, European journal of cancer.
[6] L. Boni,et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Buyse,et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Nenad Sarapa,et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Salazar,et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ying Cheng,et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M Mauer,et al. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. , 2012, European journal of cancer.
[12] A. Graser,et al. Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. , 2012 .
[13] D. Lambrechts,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.
[14] M. Parmar,et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011, The Lancet.
[15] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Stockler,et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[18] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[19] D. Sargent,et al. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials , 2009, International Journal of Clinical Oncology.
[20] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Marissa N Lassere,et al. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints , 2008, Statistical methods in medical research.
[23] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Junichi Sakamoto,et al. Exploring and validating surrogate endpoints in colorectal cancer , 2008, Lifetime data analysis.
[25] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Carrato,et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[29] Linda Mol,et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.
[30] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Hecht,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[33] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Buyse,et al. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Geert Molenberghs,et al. Validation of a longitudinally measured surrogate marker for a time-to-event endpoint , 2003 .
[36] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[37] R Henderson,et al. Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.
[38] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[39] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[40] J. Thigpen. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011 .
[41] E. Chiorean. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011 .
[42] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[43] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .